Alnylam Pharma (ALNY) Tops Q4 EPS by 19c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alnylam Pharmaceuticals (ALNY) PT Lowered to $160 at BMO Capital
February 8, 2018 12:41 PM ESTBMO Capital lowered its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $160.00 (from $165.00) while maintaining an Outperform rating.
Analyst Do Kim commented, "Alnylam reported 4Q17 GAAP EPS of ($1.48), below our ($1.28) estimate and Street's ($1.38). The wider loss was driven by higher expenses due to... More
